Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-07-29

Arcellx, Inc. (ACLX)

CEO Rami Elghandour was paid $21,402,668 in fiscal year 2024, ↓ down 14.3% from fiscal year 2023, the 99th percentile of its disclosed peer group (SEC filing 0001193125-25-084363 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$21,402,668 ↓
Rami Elghandour total, FY2024
99th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
80.8%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Rami Elghandour (Chief Executive Officer), FY2024 total compensation $21,402,668 (base salary $653,288) [exec_comp, SEC accession 0001193125-25-084363, filed 2025-04-17]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Rami Elghandour$653,288$546,000$9,342,069$10,850,151$0$0$11,160$21,402,668
Chief Executive Officer
Michelle Gilson475,960299,2503,452,4954,009,8490010,7828,248,336
Chief Financial Officer
Christopher Heery480,960302,4002,193,3872,547,4220011,1605,535,329
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Rami Elghandour$21,402,668$24,964,306$14,120,246↓ −3,561,638
Michelle Gilson8,248,3363,552,6862,114,317↑ +4,695,650
Christopher Heery5,535,3293,860,2134,914,982↑ +1,675,116

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Arcellx, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ACLX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Arcellx, Inc. Peer Teardown Report

$21,402,668 Rami Elghandour total, FY2024

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of July 29, 2026 · Source: 0001193125-25-084363 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for ACLX

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
ACLXon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order ACLX

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against ACLX
14 companies name ACLX as a compensation peer

Each company listed discloses ACLX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ACLX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the Arcellx, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Ali BehbahaniIndependent Director$355,133
Andrew GalliganIndependent Director—
David LubnerIndependent Director$359,633
Derek YoonFormer director (through FY2024)$347,133
Jill CarrollIndependent Director$353,633
Kavita PatelIndependent Director$344,633
Kristin MyersIndependent Director—
Olivia WareIndependent Director$343,633
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dividend-equivalent accruals2025-04-29—1,500——1 insider, 1 accrual row
Kavita PatelDirector2025-04-29D1,5006496,300CommonForm 4 ↗
Kavita PatelDirector2025-04-29A1,50079,990CommonForm 4 ↗
Kavita PatelDirector2025-05-20A1,50079,990CommonForm 4 ↗
Dividend-equivalent accruals2025-05-20—1,500——1 insider, 1 accrual row
Kavita PatelDirector2025-05-20D1,5005887,645CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-05-23D22,42900Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-05-23A22,42900CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-05-27D3,78664240,868CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-05-27D8,44964543,909CommonForm 4 ↗
Dividend-equivalent accruals2025-05-29—3,568——2 insiders, 2 accrual rows
David LubnerDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Jill CarrollDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2025-06-10—1,500——1 insider, 1 accrual row
Kavita PatelDirector2025-06-10D1,50067101,040CommonForm 4 ↗
Kavita PatelDirector2025-06-10A1,50079,990CommonForm 4 ↗
Ali BehbahaniDirector2025-08-12A2,62100Common, indirectForm 4 ↗
Ali BehbahaniDirector2025-08-12A1,58600CommonForm 4 ↗
Rami ElghandourDirector2025-08-28D546,9387038,422,395CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-18D3,34380267,468CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-19D3008024,000CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-26D12,39680993,155CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-29D73805,852CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-30D14,204811,157,035CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-30D1,53082125,763CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-30D5,30081426,925CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-10-03D4,88286419,870CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-10-06D1,0648691,733CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-10-15D5,36491488,315CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-11-17D3409030,600CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-02A20,49600CommonForm 4 ↗
Rami ElghandourDirector2026-01-02A55,45900CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-02D20,49600Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-02A88,54200Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-01-02D55,45900Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-01-02A208,33300Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-02D13,02100Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-02A67,70800Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-02A13,02100CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-02A13,02100CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-02A20,49600CommonForm 4 ↗
Rami ElghandourDirector2026-01-02A55,45900CommonForm 4 ↗
Rami ElghandourDirector2026-01-03A53,09800CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-03A15,34000CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-03A16,52000CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-03D16,52000Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-03D15,34000Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-01-03D53,09800Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-03A16,52000CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-03A15,34000CommonForm 4 ↗
Rami ElghandourDirector2026-01-03A53,09800CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-06A20,53000CommonForm 4 ↗
Rami ElghandourDirector2026-01-06A55,99100CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-06D13,06400Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-06A20,53000CommonForm 4 ↗
Rami ElghandourDirector2026-01-06A55,99100CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-06D20,53000Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-01-06D55,99100Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-06A13,06400CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-06A13,06400CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-12D6,13164393,286CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-13D7,43766487,213CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-14D5,88269402,997CommonForm 4 ↗
David LubnerDirector2026-01-20D6,00075450,000CommonForm 4 ↗
David LubnerDirector2026-01-20A6,000637,680CommonForm 4 ↗
David LubnerDirector2026-01-20D6,00000Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-02-11D218,50000Common, indirectForm 4 ↗
Rami ElghandourDirector2026-02-11D198,00000Common, indirectForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-17D4,15070290,552CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-17D7,14169494,231CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-19D100696,938CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-19D5,40569370,635CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-19D2,87968194,995CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-25D11,2191141,276,954CommonForm 4 ↗
Rami ElghandourDirector2026-02-27D89,91611410,243,267CommonForm 4 ↗
Rami ElghandourDirector2026-03-04D101,16400CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-03-17D5,00000CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-15D36,00000Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-15A36,0009311,760CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-16A2,110918,273CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-16D2,11000Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D67,708——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D61,538——Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2026-04-28D20,513——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D1,925——CommonForm 4 ↗
Rami ElghandourDirector2026-04-28A284,388——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28A147,745——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D88,542——Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D167,973——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D55,459——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D245,065——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D101,164——CommonForm 4 ↗
Kavita PatelDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
Jill CarrollDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D138,888——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28A138,888——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D284,388——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D147,745——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D208,333——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D810,102——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D255,965——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D120,000——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D837,602——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D1,068,005——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D218,500——Common, indirectForm 4 ↗
Rami ElghandourDirector2026-04-28D198,000——Common, indirectForm 4 ↗
Rami ElghandourDirector2026-04-28D174,887——CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D45,138——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28A45,138——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D39,194——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D13,021——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D60,096——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D76,242——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D40,000——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D132,416——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D43,604——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D10,901——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D23,749——CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D59,028——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28A59,028——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D61,590——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D20,496——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D94,596——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D70,796——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D32,500——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D40,205——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D5,000——CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D67,048——CommonForm 4 ↗
Andrew GalliganDirector2026-04-28D1,784——Derivative, Class A CommonForm 4 ↗
Andrew GalliganDirector2026-04-28D16,829——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D31,794——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D59,405——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D13,626——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D21,659——CommonForm 4 ↗
Kristin MyersDirector2026-04-28D1,784——Derivative, Class A CommonForm 4 ↗
Kristin MyersDirector2026-04-28D16,829——Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2026-04-28D27,077——Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2026-04-28D36,806——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D2,706——Common, indirectForm 4 ↗
Jill CarrollDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Jill CarrollDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
Jill CarrollDirector2026-04-28D1,479,148——Common, indirectForm 4 ↗
Andrew GalliganDirector2026-04-28D5,000——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 158 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Kavita PatelDirector2025-04-29D1,500$0$0Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2025-04-29D1,5006496,300CommonForm 4 ↗
Kavita PatelDirector2025-04-29A1,50079,990CommonForm 4 ↗
Kavita PatelDirector2025-05-20A1,50079,990CommonForm 4 ↗
Kavita PatelDirector2025-05-20D1,50000Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2025-05-20D1,5005887,645CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-05-23D22,42900Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-05-23A22,42900CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-05-27D3,78664240,868CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-05-27D8,44964543,909CommonForm 4 ↗
Kristin MyersDirector2025-05-29A1,78400Derivative, Class A CommonForm 4 ↗
David LubnerDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Jill CarrollDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Andrew GalliganDirector2025-05-29A1,78400Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2025-05-29A9,17400Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2025-06-10D1,50000Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2025-06-10D1,50067101,040CommonForm 4 ↗
Kavita PatelDirector2025-06-10A1,50079,990CommonForm 4 ↗
Ali BehbahaniDirector2025-08-12A2,62100Common, indirectForm 4 ↗
Ali BehbahaniDirector2025-08-12A1,58600CommonForm 4 ↗
Rami ElghandourDirector2025-08-28D546,9387038,422,395CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-18D3,34380267,468CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-19D3008024,000CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-26D12,39680993,155CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-29D73805,852CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-30D14,204811,157,035CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-30D1,53082125,763CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-09-30D5,30081426,925CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-10-03D4,88286419,870CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-10-06D1,0648691,733CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2025-10-15D5,36491488,315CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2025-11-17D3409030,600CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-02A20,49600CommonForm 4 ↗
Rami ElghandourDirector2026-01-02A55,45900CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-02D20,49600Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-02A88,54200Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-01-02D55,45900Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-01-02A208,33300Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-02D13,02100Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-02A67,70800Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-02A13,02100CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-02A13,02100CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-02A20,49600CommonForm 4 ↗
Rami ElghandourDirector2026-01-02A55,45900CommonForm 4 ↗
Rami ElghandourDirector2026-01-03A53,09800CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-03A15,34000CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-03A16,52000CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-03D16,52000Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-03D15,34000Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-01-03D53,09800Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-03A16,52000CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-03A15,34000CommonForm 4 ↗
Rami ElghandourDirector2026-01-03A53,09800CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-06A20,53000CommonForm 4 ↗
Rami ElghandourDirector2026-01-06A55,99100CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-06D13,06400Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-06A20,53000CommonForm 4 ↗
Rami ElghandourDirector2026-01-06A55,99100CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-01-06D20,53000Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-01-06D55,99100Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-06A13,06400CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-06A13,06400CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-12D6,13164393,286CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-13D7,43766487,213CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-01-14D5,88269402,997CommonForm 4 ↗
David LubnerDirector2026-01-20D6,00075450,000CommonForm 4 ↗
David LubnerDirector2026-01-20A6,000637,680CommonForm 4 ↗
David LubnerDirector2026-01-20D6,00000Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-02-11D218,50000Common, indirectForm 4 ↗
Rami ElghandourDirector2026-02-11D198,00000Common, indirectForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-17D4,15070290,552CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-17D7,14169494,231CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-19D100696,938CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-19D5,40569370,635CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-19D2,87968194,995CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-02-25D11,2191141,276,954CommonForm 4 ↗
Rami ElghandourDirector2026-02-27D89,91611410,243,267CommonForm 4 ↗
Rami ElghandourDirector2026-03-04D101,16400CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-03-17D5,00000CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-15D36,00000Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-15A36,0009311,760CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-16A2,110918,273CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-16D2,11000Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D67,708——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D61,538——Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2026-04-28D20,513——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D1,925——CommonForm 4 ↗
Rami ElghandourDirector2026-04-28A284,388——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28A147,745——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D88,542——Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D167,973——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D55,459——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D245,065——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D101,164——CommonForm 4 ↗
Kavita PatelDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
Jill CarrollDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D138,888——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28A138,888——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D284,388——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D147,745——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D208,333——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D810,102——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D255,965——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D120,000——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D837,602——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D1,068,005——Derivative, Class A CommonForm 4 ↗
Rami ElghandourDirector2026-04-28D218,500——Common, indirectForm 4 ↗
Rami ElghandourDirector2026-04-28D198,000——Common, indirectForm 4 ↗
Rami ElghandourDirector2026-04-28D174,887——CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D45,138——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28A45,138——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D39,194——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D13,021——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D60,096——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D76,242——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D40,000——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D132,416——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D43,604——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D10,901——Derivative, Class A CommonForm 4 ↗
Christopher HeeryCHIEF MEDICAL OFFICER2026-04-28D23,749——CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D59,028——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28A59,028——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D61,590——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D20,496——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D94,596——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D70,796——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D32,500——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D40,205——Derivative, Class A CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D5,000——CommonForm 4 ↗
Michelle GilsonCHIEF FINANCIAL OFFICER2026-04-28D67,048——CommonForm 4 ↗
Andrew GalliganDirector2026-04-28D1,784——Derivative, Class A CommonForm 4 ↗
Andrew GalliganDirector2026-04-28D16,829——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D31,794——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D59,405——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D13,626——Derivative, Class A CommonForm 4 ↗
David LubnerDirector2026-04-28D21,659——CommonForm 4 ↗
Kristin MyersDirector2026-04-28D1,784——Derivative, Class A CommonForm 4 ↗
Kristin MyersDirector2026-04-28D16,829——Derivative, Class A CommonForm 4 ↗
Kavita PatelDirector2026-04-28D27,077——Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
Olivia WareDirector2026-04-28D36,806——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D8,011——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
Ali BehbahaniDirector2026-04-28D2,706——Common, indirectForm 4 ↗
Jill CarrollDirector2026-04-28D9,174——Derivative, Class A CommonForm 4 ↗
Jill CarrollDirector2026-04-28D11,459——Derivative, Class A CommonForm 4 ↗
Jill CarrollDirector2026-04-28D1,479,148——Common, indirectForm 4 ↗
Andrew GalliganDirector2026-04-28D5,000——CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Christopher HeeryOPTION2024-01-02——60,096—$2,547,421
Rami ElghandourOPTION2024-01-02——255,965—10,850,152
Michelle GilsonOPTION2024-01-02——94,596—4,009,849
Michelle GilsonRSU2024-01-02——61,487—3,452,495
Rami ElghandourRSU2024-01-02——166,377—9,342,069
Christopher HeeryRSU2024-01-02——39,063—2,193,387
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Christopher Heery$2,193,387$0$2,547,4210.0%
Rami Elghandour9,342,069010,850,1520.0%
Michelle Gilson3,452,49504,009,8490.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Rami ElghandourPSU668,416—$51,260,823
Rami ElghandourPSU347,255—26,630,986
Rami ElghandourPSU166,377—12,759,452
Rami ElghandourPSU106,195—8,144,095
Rami ElghandourPSU70,211—5,384,482
Michelle GilsonPSU61,487—4,715,438
Christopher HeeryPSU39,063—2,995,741
Christopher HeeryPSU33,039—2,533,761
Michelle GilsonPSU30,679—2,352,773
Christopher HeeryPSU22,556—1,729,820
Rami ElghandourOption197,30756.15—
Michelle GilsonPSU22,429—1,720,080
Rami ElghandourOption837,6026.28—
Rami ElghandourOption1,068,0056.28—
Rami ElghandourOption236,28015—
Rami ElghandourOption62,50019.97—
Rami ElghandourOption127,63931.03—
Michelle GilsonOption36,6628.66—
Michelle GilsonOption16,92819.97—
Christopher HeeryOption39,71031.03—
Michelle GilsonOption36,87331.03—
Michelle GilsonOption72,91856.15—
Christopher HeeryOption3,6346.28—
Christopher HeeryOption21,8026.28—
Christopher HeeryOption75,89415—
Christopher HeeryOption20,83419.97—
Christopher HeeryOption46,32456.15—
05

Incentive-plan design — the Compensation Discussion & Analysis

The compensation committee aims to provide competitive compensation to attract and retain top talent, create a direct link between business plan achievement and employee compensation, and align employee and investor interests through long-term incentives. The company targets the 50th percentile for total cash compensation and the 75th to 90th percentile for long-term incentive compensation, emphasizing long-term equity to manage cash burn.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantMeridian Compensation Partners
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-05-2839,920,2219,482,0825,86380.8%Passed
20242024-05-2425,553,95419,766,92842,86956.33%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-05-2880.8%a
20242024-05-2456.33%b

a. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote AGAINST this proposal.”.

b. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote AGAINST this proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
David LubnerIndependent · Audit (Chair) · Compensation$60,000$0$299,633$0$0$359,633
Ali BehbahaniIndependent · Audit · Corporate Governance and Nominating (Chair)55,5000299,63300355,133
Jill CarrollIndependent · Compensation (Chair) · Corporate Governance and Nominating54,0000299,63300353,633
Derek YoonIndependent47,5000299,63300347,133
Kavita PatelIndependent · Compensation45,0000299,63300344,633
Olivia WareIndependent · Corporate Governance and Nominating44,0000299,63300343,633
Andrew GalliganIndependent · Audit · Partial-year service · Newly elected000000
Kristin MyersIndependent · Corporate Governance and Nominating · Partial-year service · Newly elected000000
Rami ElghandourEmployee director · Board Chair000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$300,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guidelinemonitoring compliance with any stock ownership guidelines.
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$306,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$306,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Arcellx, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Arcellx, Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Arcellx, Inc.2024Rami Elghandour$653,288$9,342,069$10,850,151$0$21,402,668
2Revolution Medicines, Inc.2025Mark Goldsmith812,5003,968,0768,995,114889,70014,672,390
3Vaxcyte, Inc.2025Grant Pickering800,0004,300,1598,714,048630,00014,458,937
4Cerevel Therapeutics Holdings, Inc.2022N. Anthony Coles642,735010,085,985496,70611,225,426
5Akero Therapeutics, Inc.2024Andrew (PEO)686,0002,879,1556,489,100411,60010,465,855
6Arcus Biosciences, Inc.2025Terry Rosen775,0002,199,4506,008,860658,7509,656,813
7Arrowhead Pharmaceuticals, Inc.2025Christopher Anzalone981,0466,810,29201,236,0009,029,861
8Morphic Holding, Inc.2023Praveen Tipirneni613,5023,742,9604,121,756412,9668,907,684
9CRISPR Therapeutics, AG2025Samarth Kulkarni768,6223,474,9002,768,862659,0937,678,477
10Arvinas, Inc.2025John Houston706,2362,685,8402,671,051457,0006,534,127
11Allogene Therapeutics, Inc.2025David Chang724,0002,409,5372,588,329400,0106,136,093
12Replimune Group, Inc.2026Sushil Patel700,0003,376,0031,448,325315,0005,845,982
13Beam Therapeutics, Inc.2025John Evans755,0001,513,5752,876,754662,5135,818,525
14Pliant Therapeutics, Inc.2025Bernard Coulie682,0001,810,2502,713,750204,6005,462,901
15Intellia Therapeutics, Inc.2025John Leonard708,0002,443,9201,356,32005,063,899
16Denali Therapeutics, Inc.2025Ryan Watts718,0001,151,8672,180,00304,751,515
17Relay Therapeutics, Inc.2025Sanjiv Patel707,84603,513,900424,7084,646,454
18Lyell Immunopharma, Inc.2025Lynn Seely690,173186,8062,907,551414,0004,222,265
19Zentalis Pharmaceuticals, Inc.2025Julie Eastland700,00099,77256,975441,0001,300,731

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Arcellx, Inc.140%not disclosedNoMeridian Compensation Partners
Akero Therapeutics, Inc.100%not disclosednot disclosedPearl Meyer & Partners, LLC
Allogene Therapeutics, Inc.not disclosedOption 55 · RSU 25 · PSU 20not disclosedCompensia
Arcus Biosciences, Inc.100%Options 67 · RSU 33not disclosedRadford
Arrowhead Pharmaceuticals, Inc.125%PSU 70 · RSU 30not disclosedCompensia
Arvinas, Inc.108%Options 50 · RSU 50not disclosedAon (Aon's Human Capital Solutions practice, a division of Aon plc)
Beam Therapeutics, Inc.135%Options 66 · RSU 34not disclosedPay Governance LLC
Cerevel Therapeutics Holdings, Inc.128.8%Options 100not disclosedPay Governance LLC
CRISPR Therapeutics, AGnot disclosednot disclosednot disclosedAlpine Rewards, LLC
Denali Therapeutics, Inc.145%not disclosednot disclosedAlpine Rewards
Intellia Therapeutics, Inc.115%Option 40 · RSU 40 · PSU 20Yes — TSR relative to the Nasdaq Biotechnology IndexAlpine
Lyell Immunopharma, Inc.100%not disclosedNoAlpine
Morphic Holding, Inc.120%Stock Options 50 · RSU 50not disclosedAon
Pliant Therapeutics, Inc.not disclosedOptions 67 · RSU 33not disclosedAlpine Rewards
Relay Therapeutics, Inc.100%Option 100not disclosedAon's Human Capital Solutions practice, a division of Aon plc
Replimune Group, Inc.not disclosednot disclosedNoPearl Meyer
Revolution Medicines, Inc.146%Options 70 · RSU 30not disclosedCompensia
Vaxcyte, Inc.105%not disclosednot disclosedPay Governance
Zentalis Pharmaceuticals, Inc.105%not disclosednot disclosedAnderson Pay Advisors LLC / Pay Governance LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Arcellx, Inc. in fiscal 2024?
As disclosed, Rami Elghandour (Chief Executive Officer) was the highest-paid executive at Arcellx, Inc. in fiscal 2024, with total compensation of $21,402,668.
How does Arcellx, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Rami Elghandour's total compensation ranked at the 99th percentile of Arcellx, Inc.'s disclosed peer group.
How did shareholders vote on Arcellx, Inc.'s executive compensation?
As disclosed, 80.8% of shareholders supported Arcellx, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Arcellx, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Arcellx, Inc. reported total board compensation of $306,000 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Rami ElghandourDEF 14A2025-04-170001193125-25-084363Section “Summary Compensation Table for Fiscal 2024”. As printed: 21,402,668. Filing ↗machine: r2 · c31 · span 471887–471897
2Section 01, Michelle GilsonDEF 14A2025-04-170001193125-25-084363Section “Summary Compensation Table for Fiscal 2024”. As printed: 8,248,336. Filing ↗machine: r6 · c31 · span 479143–479152
3Section 01, Christopher HeeryDEF 14A2025-04-170001193125-25-084363Section “Summary Compensation Table for Fiscal 2024”. As printed: 5,535,329. Filing ↗machine: r10 · c31 · span 486372–486381
4Section 03, Christopher Heery OPTIONDEF 14A2025-04-170001193125-25-084363Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t154 · r11 · c29 · span 516195–516204
5Section 03, Rami Elghandour OPTIONDEF 14A2025-04-170001193125-25-084363Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t154 · r3 · c29 · span 502508–502518
6Section 03, Michelle Gilson OPTIONDEF 14A2025-04-170001193125-25-084363Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t149 · r6 · c19 · span 478358–478367
7Section 03, Michelle Gilson RSUDEF 14A2025-04-170001193125-25-084363Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. Filing ↗machine: t147 · r3 · c3 · span 447453–447459
8Section 03, Rami Elghandour RSUDEF 14A2025-04-170001193125-25-084363Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. Filing ↗machine: t147 · r2 · c3 · span 446386–446393
9Section 03, Christopher Heery RSUDEF 14A2025-04-170001193125-25-084363Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. Filing ↗machine: t147 · r4 · c3 · span 448552–448558
10Section 08, David LubnerDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 359,633. Filing ↗machine: span 238534–238541
11Section 08, Ali BehbahaniDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 355,133. Filing ↗machine: span 236800–236807
12Section 08, Jill CarrollDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 353,633. Filing ↗machine: span 235090–235097
13Section 08, Derek YoonDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 347,133. Filing ↗machine: span 243683–243690
14Section 08, Kavita PatelDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 344,633. Filing ↗machine: span 240243–240250
15Section 08, Olivia WareDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 343,633. Filing ↗machine: span 241976–241983
16Section 08, Andrew GalliganDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 0. Filing ↗
17Section 08, Kristin MyersDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 0. Filing ↗
18Section 08, Rami ElghandourDEF 14A2025-04-170001193125-25-084363Section “Director Compensation”. As printed: 0. Filing ↗
19Section 02, Kavita Patel 2025-04-29Form 42025-04-290001415889-25-011532Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Kavita Patel 2025-04-29Form 42025-04-290001415889-25-011532Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Kavita Patel 2025-04-29Form 42025-04-290001415889-25-011532Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Kavita Patel 2025-05-20Form 42025-05-200000950170-25-075492Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Kavita Patel 2025-05-20Form 42025-05-200000950170-25-075492Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Kavita Patel 2025-05-20Form 42025-05-200000950170-25-075492Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Michelle Gilson 2025-05-23Form 42025-05-280000950170-25-078529Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Michelle Gilson 2025-05-23Form 42025-05-280000950170-25-078529Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Michelle Gilson 2025-05-27Form 42025-05-280000950170-25-078529Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Michelle Gilson 2025-05-27Form 42025-05-280000950170-25-078529Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Kristin Myers 2025-05-29Form 42025-05-300001415889-25-014989Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, David Lubner 2025-05-29Form 42025-05-300001415889-25-014980Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Jill Carroll 2025-05-29Form 42025-05-300000950170-25-079730Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Olivia Ware 2025-05-29Form 42025-05-300001415889-25-014986Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Kavita Patel 2025-05-29Form 42025-05-300001415889-25-014992Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Andrew Galligan 2025-05-29Form 42025-05-300001415889-25-014994Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Ali Behbahani 2025-05-29Form 42025-05-300000950170-25-079776Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Kavita Patel 2025-06-10Form 42025-06-110000950170-25-084944Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Kavita Patel 2025-06-10Form 42025-06-110000950170-25-084944Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Kavita Patel 2025-06-10Form 42025-06-110000950170-25-084944Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Ali Behbahani 2025-08-12Form 42025-08-140000950170-25-109112Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Ali Behbahani 2025-08-12Form 42025-08-140000950170-25-109112Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Rami Elghandour 2025-08-28Form 42025-08-290001415889-25-023300Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Christopher Heery 2025-09-18Form 42025-09-190001789632-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Christopher Heery 2025-09-19Form 42025-09-190001789632-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Christopher Heery 2025-09-26Form 42025-09-260001193125-25-220970Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Christopher Heery 2025-09-29Form 42025-09-290001193125-25-223675Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Christopher Heery 2025-09-30Form 42025-09-300001193125-25-225538Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Christopher Heery 2025-09-30Form 42025-09-300001193125-25-225538Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Christopher Heery 2025-09-30Form 42025-09-300001193125-25-225538Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Michelle Gilson 2025-10-03Form 42025-10-060001193125-25-232216Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Michelle Gilson 2025-10-06Form 42025-10-060001193125-25-232216Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Michelle Gilson 2025-10-15Form 42025-10-150001193125-25-240536Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Christopher Heery 2025-11-17Form 42025-11-170001193125-25-284944Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Michelle Gilson 2026-01-02Form 42026-01-060001193125-26-005085Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Rami Elghandour 2026-01-02Form 42026-01-060001193125-26-005086Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Michelle Gilson 2026-01-02Form 42026-01-060001193125-26-005085Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Michelle Gilson 2026-01-02Form 42026-01-060001193125-26-005085Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Rami Elghandour 2026-01-02Form 42026-01-060001193125-26-005086Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Rami Elghandour 2026-01-02Form 42026-01-060001193125-26-005086Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Christopher Heery 2026-01-02Form 42026-01-060001193125-26-005096Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Christopher Heery 2026-01-02Form 42026-01-060001193125-26-005096Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Christopher Heery 2026-01-02Form 42026-01-060001193125-26-005096Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Christopher Heery 2026-01-02Form 42026-01-120001193125-26-010889Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Michelle Gilson 2026-01-02Form 42026-02-180001193125-26-057469Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Rami Elghandour 2026-01-02Form 42026-02-270001193125-26-083657Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Rami Elghandour 2026-01-03Form 42026-01-060001193125-26-005086Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Michelle Gilson 2026-01-03Form 42026-01-060001193125-26-005085Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Christopher Heery 2026-01-03Form 42026-01-060001193125-26-005096Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Christopher Heery 2026-01-03Form 42026-01-060001193125-26-005096Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Michelle Gilson 2026-01-03Form 42026-01-060001193125-26-005085Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Rami Elghandour 2026-01-03Form 42026-01-060001193125-26-005086Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Christopher Heery 2026-01-03Form 42026-01-130001193125-26-012077Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Michelle Gilson 2026-01-03Form 42026-02-190001193125-26-059840Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Rami Elghandour 2026-01-03Form 42026-02-270001193125-26-083657Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Michelle Gilson 2026-01-06Form 42026-01-060001193125-26-005085Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Rami Elghandour 2026-01-06Form 42026-01-060001193125-26-005086Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Christopher Heery 2026-01-06Form 42026-01-060001193125-26-005096Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Michelle Gilson 2026-01-06Form 42026-02-250001193125-26-072579Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Rami Elghandour 2026-01-06Form 42026-02-270001193125-26-083657Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Michelle Gilson 2026-01-06Form 42026-01-060001193125-26-005085Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Rami Elghandour 2026-01-06Form 42026-01-060001193125-26-005086Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Christopher Heery 2026-01-06Form 42026-01-060001193125-26-005096Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Christopher Heery 2026-01-06Form 42026-01-140001193125-26-013284Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Christopher Heery 2026-01-12Form 42026-01-120001193125-26-010889Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Christopher Heery 2026-01-13Form 42026-01-130001193125-26-012077Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Christopher Heery 2026-01-14Form 42026-01-140001193125-26-013284Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, David Lubner 2026-01-20Form 42026-01-200001193125-26-017002Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, David Lubner 2026-01-20Form 42026-01-200001193125-26-017002Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, David Lubner 2026-01-20Form 42026-01-200001193125-26-017002Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Rami Elghandour 2026-02-11Form 42026-02-130001613689-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Rami Elghandour 2026-02-11Form 42026-02-130001613689-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Michelle Gilson 2026-02-17Form 42026-02-180001193125-26-057469Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Michelle Gilson 2026-02-17Form 42026-02-180001193125-26-057469Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Michelle Gilson 2026-02-19Form 42026-02-190001193125-26-059840Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Michelle Gilson 2026-02-19Form 42026-02-190001193125-26-059840Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Michelle Gilson 2026-02-19Form 42026-02-190001193125-26-059840Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Michelle Gilson 2026-02-25Form 42026-02-250001193125-26-072579Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Rami Elghandour 2026-02-27Form 42026-02-270001193125-26-083657Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Rami Elghandour 2026-03-04Form 42026-03-040001193125-26-092135Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Michelle Gilson 2026-03-17Form 42026-03-190001193125-26-116340Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Michelle Gilson 2026-04-15Form 42026-04-170001193125-26-161748Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Michelle Gilson 2026-04-15Form 42026-04-170001193125-26-161748Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Michelle Gilson 2026-04-16Form 42026-04-170001193125-26-161748Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Michelle Gilson 2026-04-16Form 42026-04-170001193125-26-161748Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, David Lubner 2026-04-28Form 42026-04-280001572000-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, David Lubner 2026-04-28Form 42026-04-280001572000-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Kavita Patel 2026-04-28Form 42026-04-280001670683-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Ali Behbahani 2026-04-28Form 42026-04-280001193125-26-187305Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Ali Behbahani 2026-04-28Form 42026-04-280001193125-26-187305Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Kavita Patel 2026-04-28Form 42026-04-280001670683-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Kavita Patel 2026-04-28Form 42026-04-280001670683-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Kavita Patel 2026-04-28Form 42026-04-280001670683-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Jill Carroll 2026-04-28Form 42026-04-280001193125-26-188029Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Rami Elghandour 2026-04-28Form 42026-04-280001613689-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Christopher Heery 2026-04-28Form 42026-04-280001789632-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Michelle Gilson 2026-04-28Form 42026-04-280001930862-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Andrew Galligan 2026-04-28Form 42026-04-280001417976-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Andrew Galligan 2026-04-28Form 42026-04-280001417976-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, David Lubner 2026-04-28Form 42026-04-280001572000-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, David Lubner 2026-04-28Form 42026-04-280001572000-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, David Lubner 2026-04-28Form 42026-04-280001572000-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, David Lubner 2026-04-28Form 42026-04-280001572000-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, David Lubner 2026-04-28Form 42026-04-280001572000-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, David Lubner 2026-04-28Form 42026-04-280001572000-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Kristin Myers 2026-04-28Form 42026-04-280002018445-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Kristin Myers 2026-04-28Form 42026-04-280002018445-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Kavita Patel 2026-04-28Form 42026-04-280001670683-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Olivia Ware 2026-04-28Form 42026-04-280001663771-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Olivia Ware 2026-04-28Form 42026-04-280001663771-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Olivia Ware 2026-04-28Form 42026-04-280001663771-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Olivia Ware 2026-04-28Form 42026-04-280001663771-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Ali Behbahani 2026-04-28Form 42026-04-280001193125-26-187305Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Ali Behbahani 2026-04-28Form 42026-04-280001193125-26-187305Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Ali Behbahani 2026-04-28Form 42026-04-280001193125-26-187305Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Jill Carroll 2026-04-28Form 42026-04-280001193125-26-188029Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Jill Carroll 2026-04-28Form 42026-04-280001193125-26-188029Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Jill Carroll 2026-04-28Form 42026-04-280001193125-26-188029Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Andrew Galligan 2026-04-28Form 42026-04-280001417976-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
177Section 06, 2025 voteForm 8-K2025-05-280001193125-25-129522Item 5.07 · say-on-pay result. As reported: 80.8% (votes for as printed: 39,920,221). Filing ↗
178Section 06, 2024 voteForm 8-K2024-05-290001193125-24-148245Item 5.07 · say-on-pay result. As reported: 56.33% (votes for as printed: 25,553,954). Filing ↗
179Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
180Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
181Section 09b board cost (computed)Computed——Cash 306,000 + equity 0 + all other 0 = 306,000, summed across the director compensation table rows.machine: formula: Σ = 306,000
182Arcellx, Inc. (subject), Section 10b CEO totalDEF 14A2025-04-170001193125-25-084363CEO total compensation as printed in Arcellx, Inc.'s own proxy. As printed: 21,402,668. Filing ↗machine: r2 · c31 · span 471887–471897
183Revolution Medicines, Inc., Section 10b CEO totalDEF 14A2026-04-270001193125-26-182453CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618
184Vaxcyte, Inc., Section 10b CEO totalDEF 14A2026-04-230001193125-26-173672CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207
185Cerevel Therapeutics Holdings, Inc., Section 10b CEO totalDEF 14A2023-04-280000950170-23-015766CEO total compensation as printed in Cerevel Therapeutics Holdings, Inc.'s own proxy. As printed: 11,225,426. Filing ↗machine: t23 · r2 · c29 · span 1010006–1010016
186Akero Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-280000950170-25-058964CEO total compensation as printed in Akero Therapeutics, Inc.'s own proxy. As printed: 10,465,855. Filing ↗machine: r2 · c15 · span 492349–492359
187Arcus Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-210001724521-26-000025CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749
188Arrowhead Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-01-270000879407-26-000019CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484
189Morphic Holding, Inc., Section 10b CEO totalDEF 14A2024-04-250001679363-24-000035CEO total compensation as printed in Morphic Holding, Inc.'s own proxy. As printed: 8,907,684. Filing ↗machine: r3 · c48 · span 295049–295058
190CRISPR Therapeutics, AG, Section 10b CEO totalDEF 14A2026-04-210001193125-26-165158CEO total compensation as printed in CRISPR Therapeutics, AG's own proxy. As printed: 7,678,477. Filing ↗machine: r2 · c25 · span 821649–821658
191Arvinas, Inc., Section 10b CEO totalDEF 14A2026-04-290001628280-26-028156CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930
192Allogene Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001628280-26-028948CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023
193Replimune Group, Inc., Section 10b CEO totalDEF 14A2026-07-290001104659-26-087650CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774
194Beam Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-170001193125-26-161512CEO total compensation as printed in Beam Therapeutics, Inc.'s own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178
195Pliant Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-220001746473-26-000076CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942
196Intellia Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-197283CEO total compensation as printed in Intellia Therapeutics, Inc.'s own proxy. As printed: 5,063,899. Filing ↗machine: r2 · c25 · span 749290–749299
197Denali Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics, Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614
198Relay Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186929CEO total compensation as printed in Relay Therapeutics, Inc.'s own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162
199Lyell Immunopharma, Inc., Section 10b CEO totalDEF 14A2026-04-240001140361-26-016686CEO total compensation as printed in Lyell Immunopharma, Inc.'s own proxy. As printed: 4,222,265. Filing ↗machine: r2 · c24 · span 450163–450172
200Zentalis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-300001725160-26-000027CEO total compensation as printed in Zentalis Pharmaceuticals, Inc.'s own proxy. As printed: 1,300,731. Filing ↗machine: r2 · c48 · span 319348–319357
201Section 10a, Cerevel Therapeutics Holdings, Inc. reciprocityDEF 14A—0000950170-23-015766Cerevel Therapeutics Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
202Section 10a, Morphic Holding, Inc. reciprocityDEF 14A—0001679363-24-000035Morphic Holding, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
203Section 10a, Lyell Immunopharma, Inc. reciprocityDEF 14A—0001140361-24-021008Lyell Immunopharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
204Section 10a, Akero Therapeutics, Inc. reciprocityDEF 14A—0000950170-25-058964Akero Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
205Section 10a, Allogene Therapeutics, Inc. reciprocityDEF 14A—0001628280-26-028948Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
206Section 10a, Arrowhead Pharmaceuticals, Inc. reciprocityDEF 14A—0000879407-26-000019Arrowhead Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
207Section 10a, Arvinas, Inc. reciprocityDEF 14A—0001628280-26-028156Arvinas, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
208Section 10a, Beam Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-161512Beam Therapeutics, Inc. names Arcellx, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
209Section 10a, CRISPR Therapeutics, AG reciprocityDEF 14A—0001193125-26-165158CRISPR Therapeutics, AG's most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
210Section 10a, Denali Therapeutics, Inc. reciprocityDEF 14A—0001714899-26-000054Denali Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
211Section 10a, Pliant Therapeutics, Inc. reciprocityDEF 14A—0001746473-26-000076Pliant Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
212Section 10a, Relay Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-186929Relay Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
213Section 10a, Vaxcyte, Inc. reciprocityDEF 14A—0001193125-26-173672Vaxcyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
214Section 10a, Revolution Medicines, Inc. reciprocityDEF 14A—0001193125-26-182453Revolution Medicines, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
215Section 10a, Zentalis Pharmaceuticals, Inc. reciprocityDEF 14A—0001725160-23-000078Zentalis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗
216Section 10a, Intellia Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-197283Intellia Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Arcellx, Inc.. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Arcellx, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
ACLX Peer Teardown Report